This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Oct;61(10):835-6.

doi: 10.1136/thx.2006.060772.

IL-10: Another therapeutic target in idiopathic pulmonary fibrosis?

PMID: 17008481
PMCID: PMC2104749
DOI: 10.1136/thx.2006.060772

Editorial

IL-10: Another therapeutic target in idiopathic pulmonary fibrosis?

A B Millar. Thorax. 2006 Oct.

. 2006 Oct;61(10):835-6.

doi: 10.1136/thx.2006.060772.

Author

PMID: 17008481
PMCID: PMC2104749
DOI: 10.1136/thx.2006.060772

Abstract

The need for appropriately designed clinical trials in IPF

PubMed Disclaimer

Conflict of interest statement

Competing interests: none declared.

Comment on

In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung.
Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K. Nakagome K, et al. Thorax. 2006 Oct;61(10):886-94. doi: 10.1136/thx.2005.056317. Epub 2006 Jun 29. Thorax. 2006. PMID: 16809410 Free PMC article.

Similar articles

Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.
Blease K. Blease K. Curr Opin Investig Drugs. 2008 Nov;9(11):1180-4. Curr Opin Investig Drugs. 2008. PMID: 18951297 Review.
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Oku H, et al. Eur J Pharmacol. 2008 Aug 20;590(1-3):400-8. doi: 10.1016/j.ejphar.2008.06.046. Epub 2008 Jun 16. Eur J Pharmacol. 2008. PMID: 18598692
[Antioxidative treatment of idiopathic pulmonary fibrosis].
Behr J, Costabel U, Buhl R. Behr J, et al. Pneumologie. 2006 Jun;60(6):373-5. doi: 10.1055/s-2006-932209. Pneumologie. 2006. PMID: 16761233 German. No abstract available.
Optimal treatment for idiopathic pulmonary fibrosis.
Maher TM, Wells AU. Maher TM, et al. Thorax. 2008 Dec;63(12):1120-1; author reply 1121. Thorax. 2008. PMID: 19020278 No abstract available.
Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases.
Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Joshi BH, et al. Vitam Horm. 2006;74:479-504. doi: 10.1016/S0083-6729(06)74019-5. Vitam Horm. 2006. PMID: 17027527 Review.

See all similar articles

Cited by

Network Pharmacology-Based Mechanistic Investigation of Jinshui Huanxian Formula Acting on Idiopathic Pulmonary Fibrosis.
Liu T, Xu P, Qi S, Ke S, Hu Q, Zhao P, Li J. Liu T, et al. Evid Based Complement Alternat Med. 2021 Jul 7;2021:8634705. doi: 10.1155/2021/8634705. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34306156 Free PMC article.
Pulmonary fibrosis: pathogenesis, etiology and regulation.
Wilson MS, Wynn TA. Wilson MS, et al. Mucosal Immunol. 2009 Mar;2(2):103-21. doi: 10.1038/mi.2008.85. Epub 2009 Jan 7. Mucosal Immunol. 2009. PMID: 19129758 Free PMC article. Review.
Botanical formulation HX110B ameliorates PPE-induced emphysema in mice via regulation of PPAR/RXR signaling pathway.
Lee S, Lee CH, Lee J, Jeong Y, Park JH, Nam IJ, Lee DS, Lee HM, Ahn SY, Kim E, Jeong S, Yu SS, Lee W. Lee S, et al. PLoS One. 2024 Jul 25;19(7):e0305911. doi: 10.1371/journal.pone.0305911. eCollection 2024. PLoS One. 2024. PMID: 39052574 Free PMC article.
The role of Interleukin-10 and 13 in tuberculosis-associated pulmonary dysfunction.
Namaei MH, Mortazavi-Moghaddam SG, Eslami-Manoochehri R, Zardast EM. Namaei MH, et al. Caspian J Intern Med. 2019 Spring;10(2):223-227. doi: 10.22088/cjim.10.2.223. Caspian J Intern Med. 2019. PMID: 31363402 Free PMC article.
IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN/AKT/ERK pathway.
Li Y, Yin H, Yuan H, Wang E, Wang C, Li H, Geng X, Zhang Y, Bai J. Li Y, et al. BMC Pulm Med. 2024 Sep 11;24(1):443. doi: 10.1186/s12890-024-03260-x. BMC Pulm Med. 2024. PMID: 39261827 Free PMC article.

See all "Cited by" articles

References

1. Millar A. Anti‐cytokine therapy in fibrosing alveolitis: where are we now? Respir Res 200013–5. - PMC - PubMed
1. Raghu G, Brown K K, Bradford W Z.et al A placebo‐controlled trial of interferon gamma‐1β in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004350125–133. - PubMed
1. Azuma A, Nukiwa T, Tsuboi E.et al Double‐blind, placebo‐controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 20051711040–1047. - PubMed
1. Demedts M, Behr J, Buhl R.et al High‐dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 20053532229–2242. - PubMed
1. Nakagome K, Dohi M, Okunishi K.et al In vivo IL‐10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF‐β in the lung. Thorax 200661886–894. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information